After numerous procedures and intravesical therapies, a patient's bladder function can become so poor that removing it (cystectomy) is not a treatment failure, but a positive intervention to improve their quality of life. This reframes the goal from preserving the organ to preserving patient well-being.

For bladder cancer patients with micrometastatic disease, the standard cystectomy requires a significant delay for the operation and recovery. This window may allow unseen metastases to progress, suggesting that upfront, effective systemic therapy is more critical for survival than immediate major surgery.

During the consensus meeting, patient advocates successfully argued for a highly robust definition of "event-free survival." The final definition counts not just cancer recurrence, but also the need for any additional standard-of-care treatment—including intravesical therapy—as an "event," reflecting the patient's perspective on what constitutes a successful outcome.

In the SURE-01 trial, nearly a third of patients declined radical cystectomy after strong responses to sacituzumab govitecan. This patient-driven decision highlights a significant, growing interest in bladder preservation, pushing the field to validate less invasive approaches for select patients.

The excitement around new systemic therapies has already created a "Wild West" environment where patient and surgeon motivation for cystectomy has plummeted. This cultural shift is outpacing prospective data, raising concerns that patients are making major decisions outside of rigorous clinical trials.

While bladder preservation is a key goal, there is an unavoidable risk. Forgoing definitive local treatment like surgery means a subset of patients will not be cured by systemic therapy alone and will miss their opportunity for a potentially curative operation, a crucial ethical consideration.

Contrary to outdated perceptions, quality of life after radical cystectomy has dramatically improved. Patients can return to highly active lifestyles, including professional sports and marathons, debunking the myth that the procedure ends an active life. This is a crucial patient counseling point.

While new systemic agents dominate MIBC discussions, chemo-radiation remains a critical treatment, especially for patients unsuitable for radical cystectomy due to age or comorbidities. For these individuals, it offers a potentially curative, bladder-preserving alternative that avoids the high risks and sequelae of major surgery.

A notable trend is patients achieving a strong response to neoadjuvant therapy and then refusing definitive local treatment like cystectomy. Experts caution against this "off-study" approach, as it deviates from the curative backbone of care and undermines the ability to build an evidence base for bladder preservation strategies.